Dr Chopra talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about a newly discovered mechanism of action for immunomodulatory thalidomide analogues.

These act by modulating the way certain proteins are degraded, thus preventing the growth of certain tumours such as lymphoma.

This also negatively affects B-Cell development, but in turn activates T-Cells.

The therapy could be combined with other antibodies and vaccines.